BOSTON/Massachusetts, TORONTO/Canada, March 3 /CNW/ - BIKAM, pioneers in
the discovery and development of potential therapeutic agents for the
treatment of degenerative eye diseases and ocular disorders and Dalton
Medicinal Chemistry, have jointly announced an exclusive worldwide
collaboration and agreement to discover and develop new therapeutics for unmet
needs in ophthalmology.
Dalton Medicinal Chemistry will utilize their proprietary insights to
advance several novel classes of compounds against selected BIKAM targets.
BIKAM will advance these agents with their cutting edge battery of biological
assays and delivery methodologies.
David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have
the opportunity to work with the creative team at Dalton Medicinal Chemistry
in the discovery and development of new entities for treating eye diseases.
Their expertise, together with our propriety and leading position will quickly
deliver important new medicines."
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are
delighted to have this opportunity to work with BIKAM in the discovery and
development of much needed agents to treat these debilitating diseases".
BIKAM, Inc., is a biopharmaceutical company focused on the development of
novel therapeutics for the treatment of degenerative eye diseases and
disorders. BIKAM is building a portfolio of product candidates based on
patented technologies that were identified at the University of Florida,
Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners
and Fidelity Biosciences.
About Dalton Pharma Services & Dalton Medicinal Chemistry
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health
Canada contract pharmaceutical manufacturer that supplies chemistry and
analytical services to the biotechnology and pharmaceutical industries in the
areas of chemistry and fine chemical manufacture. Dalton Medicinal Chemistry
collaborates with select partners to deliver innovative, high quality
medicinal chemistry capabilities to advance partners drug discovery pipelines.
Dalton provides cGMP manufacturing and sterile filling services to its
customers at any stage of the regulatory process (Phase I, II, III or
commercial). In its state of the art cGMP facilities, Dalton produces active
pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts
sterile fills to produce batches of finished drug product in vials or
syringes, either aseptically filled or terminally sterilized, under fully
validated conditions. In addition, Dalton's analytical chemistry laboratory
offers method development, validation and ICH stability programs to its
For further information:
For further information: BIKAM, Inc.: David Garvey, (617) 252-1117;
Dalton Pharma Services: Peter Pekos, (416) 661-2102, www.dalton.com